Intravitreal ranibizumab therapy was associated with thinning of the subfoveal choroid in patients treated for unilateral idiopathic subfoveal choroidal neovascularization, a study found. The prospective study included 16 patients with unilateral idiopathic subfoveal choroidal neovascularization who underwent a single intravitreal injection of 0.5 mg ranibizumab and subsequent injections as needed. Investigators used enhanced depth imaging optical coherence tomography to measure subfoveal choroidal thickness (SFCT). Mean patient age was 31.9 years. Visual acuity was also evaluated.